Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Poised to Gain Steady Boost at CAGR of 7.2% Through 2025

Albany, NY -- (SBWIRE) -- 03/12/2018 -- The rising prevalence of exocrine pancreatic insufficiency around the world has created significant demand for effective treatment methods. It has been analyzed that EPI results due to a number of conditions such as cystic fibrosis, cytomegalovirus infection, pancreatic cancer, chronic pancreatitis, and HIV/AIDS. Owing to the alarming increase in the prevalence of cystic fibrosis, the risk of EPI also increases substantially. These facts have resulted for market growth of EPI therapeutics and diagnostic widely, finds a new study published to the online repository of Market Research Hub, and captioned as "Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025". According to the key evaluations, the global EPI therapeutics and diagnostics market was valued at US$3,397.5 mn in 2016 and is projected to reach US$6,414.4 mn by 2025, expanding at a remarkable CAGR of 7.2% from 2017 to 2025.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.